"Encompassing all elements of vascular care, including diagnostic evaluations and medical management, non-invasive testing, surgical care, diagnostic angiography and endovascular therapeutics (minimally invasive procedures), and inpatient services and critical care."

During the past decade, UC Davis Vascular Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "UC Davis Vascular Center" are "Peripheral Arterial Disease" (1 trials) and "Peripheral Vascular Diseases" (1 trials). Many other conditions were trialed in "UC Davis Vascular Center" in a lesser frequency.

Most popular intervention types in "UC Davis Vascular Center" are "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "BARD LifeStent" (1 trials), "Bypass" (1 trials), "Silverhawk Plaque Excision" (1 trials) and "TIGRIS Vascular Stent" (1 trials). Other intervention names were less common.

The vast majority of trials in "UC Davis Vascular Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "UC Davis Vascular Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in UC Davis Vascular Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UC Davis Vascular Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".